CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Mizuho Medy Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Mizuho Medy Co Ltd
5-4, Fujinoki-machi
Phone: +81 942850303p:+81 942850303 TOSU-SHI, SAG  841-0048  Japan Ticker: 45954595

Business Summary
MIZUHO MEDY CO., LTD. is a Japan-based company principally engaged in-vitro diagnostic pharmaceuticals business. The Company mainly provides in-vitro diagnostic pharmaceuticals, including immune serum test drugs, biochemical test drugs, urine and feces test drugs, microbial test drugs, blood test drugs, pathological test drugs and others, in hospital and medical practitioner fields. In addition, the Company also provides over-the-counter (OTC) drugs to pharmacies and drug stores, and sells fruit tree virus test drugs to which they apply the technology of immune serology test to agricultural test centers.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Representative Director FuminariKarakawa 73 3/29/2016 11/1/1977
Managing Director, Director of Development Planning MasashiImamura 63 3/1/2013 3/1/2010
Chief Director of Sales, Director of Overseas Business, Director ToshioKambara 59 3/1/2015 3/1/2015
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 180 (As of 12/31/2023)
Outstanding Shares: 9,524,397 (As of 12/31/2023)
Shareholders: 8,549
Stock Exchange: TYO
Fax Number: +81 942850312


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024